FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Zevra Therapeutics in a report issued on Thursday, August 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.57 for the year, up from their prior forecast of $0.55. HC Wainwright currently has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.56 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2026 earnings at $0.13 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 58.95% and a net margin of 42.82%.

ZVRA has been the subject of several other research reports. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Weiss Ratings downgraded shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. BTIG Research cut their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. Finally, Cantor Fitzgerald raised their price objective on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $27.29.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $11.88 on Friday. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $15.03. The business’s fifty day moving average is $12.32 and its 200-day moving average is $10.57. The stock has a market cap of $702.35 million, a PE ratio of 12.91 and a beta of 0.91.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in shares of Zevra Therapeutics during the second quarter worth $2,846,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares during the period. Quantinno Capital Management LP increased its stake in Zevra Therapeutics by 114.1% in the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after purchasing an additional 17,065 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Zevra Therapeutics during the 1st quarter worth about $11,184,000. 35.03% of the stock is owned by institutional investors.

Key Headlines Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported $39.7 million in second-quarter revenue, up 53% year over year and above the roughly $34 million consensus estimate. EPS of $0.25 also surpassed analyst expectations of approximately $0.08–$0.11. MIPLYFFA generated $30.2 million in revenue, supporting the company’s commercial growth. Zevra Therapeutics Q2 earnings article
• Positive Sentiment: Cash generation and financial flexibility improved. The company reported a strong cash position of $260.2 million and positive operating execution, giving it additional resources to support MIPLYFFA commercialization and future development programs. Zevra Q2 2026 financial results and corporate update
• Positive Sentiment: Regulatory and patent updates strengthened the MIPLYFFA outlook. Zevra expects a European Commission CHMP reexamination opinion in the fourth quarter, while MIPLYFFA’s Orange Book listing has been extended to 2041. The developments may improve visibility around potential European approval and provide longer U.S. market exclusivity. Zevra CHMP reexamination and Orange Book update
• Positive Sentiment: Citizens JMP raised its price target to $28 from $25 and maintained a “market outperform” rating. The new target is well above the recent trading level and reinforces bullish analyst sentiment; several analysts have targets in the mid-$20s to mid-$30s. Benzinga analyst price target report
• Neutral Sentiment: Institutional positioning was mixed, with some funds adding shares and others reducing or exiting positions. This suggests continued disagreement about Zevra’s valuation and execution outlook.
• Negative Sentiment: Recent insider activity showed sales by executives and no reported insider purchases over the past six months. While these transactions do not necessarily reflect business fundamentals, they may temper investor enthusiasm.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.